Related Experiment Videos
Overview of hypercalcemia of malignancy
1Oncology Pharmacy Services, Inc., 4201 Wilson Boulevard, #110-545, Arlington, VA 22203, USA. OncRxSvc@aol.com
Summary
Malignancy-associated hypercalcemia stems from increased bone breakdown and kidney calcium reabsorption, often driven by parathyroid hormone-related protein (PTHrP). Accurate diagnosis requires ruling out other causes like primary hyperparathyroidism.
Area of Science:
- Endocrinology
- Oncology
- Nephrology
Background:
- Calcium homeostasis is regulated by parathyroid hormone, calcitonin, and cholecalciferol.
- Hypercalcemia is defined as serum calcium > 12 mg/dL, adjusted for albumin.
- Malignancy-associated hypercalcemia (HCM) is a common complication of cancer.
Purpose of the Study:
- Discuss the etiology, pathophysiology, and diagnosis of HCM.
- Elucidate the role of parathyroid hormone-related protein (PTHrP) in HCM.
- Differentiate HCM from other causes of hypercalcemia.
Main Methods:
- Review of literature on calcium metabolism and hypercalcemia in malignancy.
- Analysis of the mechanisms of bone resorption and renal reabsorption in HCM.
- Discussion of diagnostic criteria and differential diagnosis for hypercalcemia.
Main Results:
- HCM primarily results from increased osteoclast-mediated bone resorption.
- Parathyroid hormone-related protein (PTHrP) is the main mediator in most tumors, stimulating bone resorption.
- Transforming growth factor-beta (TGF-beta) may perpetuate the cycle by stimulating tumor cells.
Conclusions:
- Understanding the pathophysiology of HCM is crucial for diagnosis and management.
- PTHrP plays a central role in the development of HCM.
- Differential diagnosis, particularly excluding primary hyperparathyroidism, is essential for accurate HCM diagnosis.